Metabolic syndrome in rheumatoid arthritis: Case control study

BMC Musculoskeletal Disorders

Volumn 14, Issue , 2013, Pages

  Rostom, Samira ^a   Mengat, Mariam ^a   Lahlou, Racha ^a   Hari, Asmaa ^a   Bahiri, Rachid ^a   Hajjaj Hassouni, Najia ^a  

^a MOHAMMED V UNIVERSITY   (Morocco)

Author keywords

Disease activity; Metabolic syndrome; Rheumatoid arthritis

Indexed keywords

GLUCOCORTICOID; HYDROXYCHLOROQUINE; METHOTREXATE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREDICTOR VARIABLE; PREVALENCE; RHEUMATOID ARTHRITIS;

ADULT; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED;

EID: 84876692184     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-14-147     Document Type: Article

References (44)

1. Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rall LC, Roubenoff R, Rheumatology (Oxford) 2004 43 1219 1223 10.1093/rheumatology/keh321
2. Association of body composition with disability in rheumatoid arthritis: impact of appendicular fat and lean tissue mass. Giles JT, Bartlett SJ, Andersen RE, Fontaine KR, Bathon JM, Arthritis Rheum 2008 59 1407 1415 10.1002/art.24109 18821641
3. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980 s and 1990s. Goodson N, Marks J, Lunt M, Symmons D, Ann Rheum Dis 2005 64 1595 1601 10.1136/ard.2004.034777 15843450
4. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, McInnes IB, Haentzschel H, Gonzalez-Gay MA, Provan S, Semb A, Sidiropoulos P, Kitas G, Smulders YM, Soubrier M, Szekanecz Z, Sattar N, Nurmohamed MT, Ann Rheum Dis 2010 69 325 331 10.1136/ard.2009.113696 19773290
5. Relationship between obesity, insulin resistance, and coronary heart disease risk. Abbasi F, Brown BW Jr, Lamendola C, McLaughlin T, Reaven GM, J Am Coll Cardio 2002 40 937 943 10.1016/S0735-1097(02)02051-X
6. Metabolic syndrome: definitions and controversies. Eva K, Panagiota Pervanidou, Gregory Kaltsas and George Chrousos, BMC Med 2011 9 48 10.1186/1741-7015-9-48 21542944
7. Metabolic syndrome and subclinical atherosclerosis in rheumatoid arthritis. Dessein PH, Tobias M, Veller MG, J Rheumatol 2006 33 2425 2432 17080519
8. Increased prevalence of metabolic syndrome associated with rheumatoid arthritis in patients without clinical cardiovascular disease. Crowson CS, Myasoedova E, Davis JM, Matteson EL, Roger VL, Therneau TM, Fitz-Gibbon P, Rodeheffer RJ, Gabriel SE, J Rheumatol 2011 38 1 29 35 10.3899/jrheum.100346 20952464
9. The practical value of biologics registries in Africa and Middle East: challenges and opportunities. Hajjaj-Hassouni N, Al-Badi M, Al-Heresh A, Al-Emadi S, El Bawendi A, El Garf A, El Hadidi K, Halabi H, Hammoudeh M, El Hassani S, Al Maaini M, Nahar I, Ladjouze Rezig A, Sellami S, Sweiri W, Alswailem R, Traub B, Uthman I, Van Duuren E, Zakraoui L, El Zorkany B, Carmona L, Dougados M, Clin Rheumatol 2012 31 3 407 16 10.1007/s10067-011-1918-8. Epub 2012 Jan 7. Review 22228237
10. Profile and course of early rheumatoid arthritis in Morocco: a two-year follow-up study. Benbouazza K, Benchekroun B, Rkain H, Amine B, Bzami F, Benbrahim L, Atouf O, Essakalli M, Abouqal R, Dougados M, Hajjaj-Hassouni N, BMC Musculoskelet Disord 2011 Nov 23 12 266 10.1186/1471-2474-12-266
11. Prevalence of overweight in Moroccan patients with rheumatoid arthritis and its relationships with disease features. Ibn Yacoub Y, Amine B, Laatiris A, Wafki F, Znat F, Hajjaj-Hassouni N, Clin Rheumatol 2012 Mar 31 3 479 82 10.1007/s10067-011-1874-3
12. Rheumatoid factor and antibodies against citrullinated peptides in Moroccan patients with rheumatoid arthritis: association with disease parameters and quality of life. Ibn Yacoub Y, Amine B, Laatiris A, Hajjaj-Hassouni N, Clin Rheumatol 2012 Feb 31 2 329 34 10.1007/s10067-011-1820-4
13. Rheumatoid arthritis in the developing world. Kalla AA, Tikly M, Best Pract Res Clin Rheumatol 2003 17 5 863 875 10.1016/S1521-6942(03)00047-0 12915162
14. Tak PP (2008) Rheumatoid arthritis in the United Arab Emirates. Badsha H, Kong KO, Clin Rheumatol 2008 27 6 739 742 10.1007/s10067-007-0782-z 17973153
15. Smokers and non smokers with rheumatoid arthritis have similar clinical status: data from the multinational QUEST-RA database. Naranjo A, Toloza S, Naranjo A, Toloza S, Guimaraes Da Silveira I, Lazovskis J, Hetland ML, Hamoud H, Peets T, Mäkinen H, Gossec L, Herborn G, Skopouli FN, Rojkovich B, Aggarwal A, Minnock P, Cazzato M, Yamanaka H, Oyoo O, Rexhepi S, Andersone D, Baranauskaite A, Hajjaj-Hassouni N, Jacobs JW, Haugeberg G, Sierakowski S, Ionescu R, Karateew D, Dimic A, Henrohn D, Gogus F, Badsha H, Choy E, Bergman M, Sokka T, Clin Exp Rheumatol 2010 28 6 820 7 21205460
16. Risk factor profiles for atherosclerotic cardiovascular disease in black and other Africans with established rheumatoid arthritis. Solomon A, Christian BF, Norton GR, Woodiwiss AJ, Dessein PH, J Rheumatol 2010 May 37 5 953 60 10.3899/jrheum.091032
17. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Arthritis Rheum 1988 31 315 324 10.1002/art.1780310302 3358796
18. Modified disease activity scores that includes twenty-eightjoint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Prevoo ML, van't Hof MA, Kupper HH, van Leeuwen MA, van de Putte LB, van Riel L, Arthritis Rheum 1995 38 44 48 10.1002/art.1780380107 7818570
19. Psychometric evaluation of a Moroccan version of health assessment questionnaire for use in Moroccan patients with rheumatoid arthritis. Abourazzak FE, Benbouazza K, Amine B, Bahiri R, Lazrak N, Bzami F, Jroundi I, Abouqal R, Guillemin F, Hajjaj-Hassouni N, Rheumatol Int 2008 28 12 1197 203 10.1007/s00296-008-0595-7 18535829
20. In Report of a WHO expert committee. Physical Status the Use and Interpretation of Anthropometry, World Health Organ Tech Rep Ser 1995 854 1 452 8594834
21. Metabolic syndrome-a new world-wide definition. Alberti KG, Zimmet P, Shaw J, A Consensus Statement from the International Diabetes Federation Diabet Med 2006 23 5 469 80
22. The metabolic syndrome: more than the sum of its parts? Reilly MP, Rader DJ, Circulation 2003 108 1546 1551 10.1161/01.CIR.0000088846.10655.E0 14517150
23. Comment on the provisional report from the WHO consultation. Balkau B, Charles MA, Diabet Med 1999 16 442 443 10342346
24. Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Alberti KGMM, Zimmet PZ, Diabet Med 1998 15 539 553 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0. CO;2-S 9686693
25. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). NCEP Expert Panel, JAMA 2001 285 2486 2497 10.1001/jama.285.19.2486 11368702
26. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ, Circulation 2004 110 227 239 10.1161/01.CIR.0000133317.49796.0E 15249516
27. The metabolic syndrome: a new worldwide definition. Alberti KG, Zimmet P, Shaw J, Lancet 2005 366 1059 1062 10.1016/S0140-6736(05)67402-8 16182882
28. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr, Circulation 2009 120 1640 1645 10.1161/CIRCULATIONAHA.109.192644 19805654
29. Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, crosssectional, controlled, study. Karvounaris SA, Sidiropoulos PI, Papadakis JA, Spanakis EK, Bertsias GK, Kritikos HD, Ganotakis ES, Boumpas DT, Ann Rheum Dis 2007 66 28 33 16793841
30. The metabolic syndrome: The crossroads between rheumatoid arthritis and cardiovascular risk. Gremese E, Ferraccioli G, Autoimmun Rev 2011 10 10 582 9 10.1016/j.autrev.2011.04.018 21539940
31. Metabolic syndrome in South Asian immigrants: more than low HDL requiring aggressive management. Sunita D, Rebecca H, Jo W, James V, Kamal G, Lei D, Butler MG, Lipids Health Dis 2011 10 45 10.1186/1476-511X-10-45 21410987
32. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani A, Atherosclerosis 2008 196 756 63 10.1016/j.atherosclerosis.2007.01.004 17266963
33. Prevalence and factors associated with metabolic syndrome in patients with rheumatoid arthritis and systemic lupus erythematosus. Zonana-Nacach A, Santana-Sahagun E, Jimenez-Balderas FJ, Coronel C, J Clin Rheumatol 2008 14 74 77 10.1097/RHU.0b013e31816b2faa 18391674
34. The metabolic syndrome is amplified in hypothyroid rheumatoid arthritis patients: a cross-sectional study. Raterman HG, van Eijk IC, Voskuy AE, Peter MJ, Dijkmans BA, van Halm VP, Simsel S, Lems WF, Nurmohamed MT, Ann Rheum Dis 2010 69 39 42 10.1136/ard.2008.100776 19103637
35. Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross sectional study. Toms T, Panoulas V, John H, Douglas KM, Kitas GD, Arthritis Res Ther 2009 11 4 110 10.1186/ar2765 19607680
36. Rheumatoid cachexia is associated with dyslipidemia and low levels of atheroprotective natural antibodies against phosphorylcholine but not with dietary fat in patients with rheumatoid arthritis: a cross-sectional study. Elkan AC, Hakansson N, Frostegard J, Cederholm T, Hafstrom I, Arthritis Res Ther 2009 11 4 37 19284557
37. The metabolic syndrome: prevalence and risk factors in the urban population of Ho Chi Minh City. le Son NT, Kunii D, Hung NTK, Sakai T, Yamamoto S, Diabetes Res Clin Pract 2005 67 243 250 10.1016/j.diabres.2004.07.014 15713357
38. The influence of age and body mass index on the metabolic syndrome and its components. Alexander CM, Landsman PB, Grundy SM, Diabetes Obes Metab 2008 10 246 250 10.1111/j.1463-1326.2006.00695.x 18269640
39. Insulin resistance in early untreated rheumatoid arthritis patients. Shahin D, Eltoraby E, Mesbah A, Houssen M, Clin Biochem 2010 43 661 665 10.1016/j.clinbiochem.2010.01.012 20144599
40. Association of physical inactivity with increased cardiovascular risk in patients with rheumatoid arthritis. Metsios GS, Stavropoulos-Kalinoglou A, Panoulas VF, Wilson M, Nevill AM, Koutedakis Y, Kitas GD, Eur J Cardiovasc Prev Rehabil 2009 16 188 19 10.1097/HJR.0b013e3283271ceb 19238083
41. Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: a cross-sectional study. Toms TE, Panoulas VF, Douglas KM, Griffiths HR, Kitas GD, Arthritis Res Ther 2008 10 145 10.1186/ar2578 19091101
42. Glucocorticoids and insulin sensitivity in rheumatoid arthritis. Dessein PH, Joffe BI, Stanwix AE, Christian BF, Veller M, J Rheumatol 2004 31 867 74 15124244
43. Low-dose glucorticoid therapy in rheumatoid arthritis: an obligatory therapy. Bijlsma JWJ, van der Goes MC, Hoes JN, Jacobs JWG, Buttgereit F, Kirwan J, Ann N Y Acad Sci 2010 1193 123 126 10.1111/j.1749-6632.2009.05342.x 20398017
44. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Sattar N, McConnachie A, Shaper AG, Blauw GJ, Buckley BM, de Craen AJ, Ford I, Forouhi NG, Freeman DJ, Jukema JW, Lennon L, Macfarlane PW, Murphy MB, Packard CJ, Stott DJ, Westendorp RG, Whincup PH, Shepherd J, Wannamethee SG, Lancet 2008 371 1927 1935 10.1016/S0140-6736(08)60602-9 18501419